The rapid rise, virulent spread, ongoing mitigation efforts, and ubiquitous impact of COVID-19 have been a harsh pressure test for scientists and health systems around the world. It has also been an urgent call to action, raising time-sensitive questions about the disease and its consequences.
Such questions – and many more – will require deep, broad, and high-quality data assets to answer. They also need an accelerated timeline for discussion and debate. COVID-19 has disrupted healthcare for everyone; we must understand the extent and the short and long term impact, quickly.
In an effort to support timely, sharable research, IQVIA is waiving data access fees for academic researchers to two IQVIA data technology platforms through October 2020
E360™ is the industry leading SaaS technology platform used to perform scalable analytics across a global portfolio of large and complex real world data sets. E360™ will provide access to EMR data from France, Germany, and the UK.
SMART brings together the industry’s leading syndicated information assets onto a robust business intelligence platform. Access to SMART will provide a view into national syndicated insights from prescribing, fulfillment channel, sales volumes, promotional, managed care market access as well as medical device and supply tracking.
In addition, U.S. prescription and medical claims data can be made available as needed to support specific analyses.
Research conducted under this collaborative is intended to be evidence based and accelerate the development and sharing of research and insights in public forums.
Please note the number of access opportunities are limited. If you are interested in applying for access, submit an application today.
For more information, please consult these frequently asked questions.
The IQVIA Institute for Human Data Science regularly supports empirically rigorous, policy-relevant research to improve the quality and cost-effectiveness of healthcare. Recent project topics include examinations of trends in prescription opioid use, analyses of global and U.S. drug pricing dynamics, investigations on antibiotic utilization, and explorations into the use of technology and innovation on health systems.
For updates about the Human Data Science Research Collaborative, follow the IQVIA Institute on Twitter and LinkedIn and join the IQVIA Institute mailing list.
We are ready to help you better understand and benefit from the work of the IQVIA Institute for Human Data Science. Please get in touch today to learn more.